In a single month, three reports describe different views of China's economic future
The director known for adding depth to the mundane will make the case that Gap's "Dress Normal" doesn't equal "dress boring"
Three times more money has been spent on the race for the state's school's chief than on the governor's race
An IT expert offers an estimate of what a 50-employee small business might spend to protect against cyberattacks
A slowdown in funding could end the growth of U.S. oil production
Independent developer Lucas Menge took it upon himself to adapt the smartwatch's home screen for the iPhone
Starbucks will start a coffee delivery program in late 2015, giving other companies' employees one fewer excuse to leave the office
New government rules could block 500 colleges from federal aid money and put hundreds more in danger of losing it
Candy sales are increasing, but big drugstores and supermarkets benefit more than local candy shops
King of Prussia, Pa.
Founders: Dr. Robert Lefkowitz and Dr. Howard Rockman
VC Investment over the last four quarters: $26.1 million
Trevena, founded in January 2008, is a drug discovery company developing pharmaceuticals that target what are known as G-protein coupled receptors. Such drugs make up more than 40% of marketed drugs today, according to Trevena. The company's drug discovery platform is based on research from Duke University Medical Center, including that of founder and National Medal of Science winner Robert Lefkowitz.
Key to startup success: "We've been able to generate the strong investor support for this idea [because] the technology and the opportunity here is very, very unique, and the possibility of unlocking new areas of biology is so significantly different from what's currently out there."